October 30, 2026

The Manager (CRD) **The BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai- 400001	The Manager – Listing Department **National Stock Exchange of India Ltd** Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (East) Mumbai - 400 051
Scrip Code: 530117	**Symbol: PRIVISCL**

Dear Sir / Madam,

Sub: Investors Presentation – Financial & Operation Review for quarter and half year ended September 30, 2026

Pursuant to our letter dated October 23, 2026, intimating about Earnings Conference Call to be held on Friday, October 30, 2026, at 04:00 pm IST and regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we also enclose herewith the Investors Presentation on Financial & Operational Review for the quarter, and half year ended September 30, 2026.

The Investors' Presentation is also being uploaded on the Company's website www.privi.com.

You are requested to kindly take the same on record.

Thanking you,

Yours Sincerely,
For **Privi Speciality Chemicals Limited**

Ashwini Saumil Shah
Digitally signed by Ashwini Saumil Shah
Date: 2026.10.30 09:34:09 +05'30'

Ashwini Saumil Shah
Company Secretary

Encl: Investors Presentation

Vision to Value.

A Purpose Backed by Momentum

PRIVI SPECIALITY CHEMICALS LIMITED

Investor Presentation
Q2 & H1 FY26-27

We do different things, We do things differently

Safe Harbor

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Privi Speciality Chemicals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

Index

01

Highlight’s

Strategic vision and performance overview

02

Q2 & H1 FY27 Results

Consolidated performance metrics

03

Company Overview

About Us

04

Growth Strategy

Strategic priorities and outlook

Highlights

- Q2 FY27 extended our momentum with **strong financial performance**, reflecting the resilience of our business model and disciplined execution even under difficult global headwinds.
- We delivered **Rs 773.16 Cr of total income representing 13.90% year-on-year growth, Rs 212.49 Cr of EBITDA with 16.66 % year-on-year growth and Rs 117.03 Cr of Net Profit with 24.61% year-on-year growth**, supported by broad-based demand across domestic and export markets. We are positive to continue the momentum.
- Our business has continued to be **resilient** despite adverse global headwinds.
- Our **diversified geographic presence** has supported stability across markets.
- The **expansion projects are progressing** as planned and will be ready for commercial operations in second half of 2028.
- **Our new products are expected to expand our addressable market**, deepen customer relationships, and contribute meaningfully to growth in the coming years.
- With a **strong balance sheet, healthy cash flows**, and a clear strategic roadmap, we remain well positioned for the future.

Performance at a glance – Q2 & H1 FY27

Q2 FY27

Revenue (Rs. Cr)	EBITDA (Rs. Cr)	EBITDA Margin (%)	PAT (Rs. Cr)
773.16 (+13.9% YoY)	212.49 (+16.7% YoY)	27.48% (+65 bps YoY)	117.03 (+24.6% YoY)

H1 FY27

Revenue (Rs. Cr)	EBITDA (Rs. Cr)	EBITDA Margin (%)	PAT (Rs. Cr)
1,454.59 (+16.7% YoY)	379.96 (+17.6% YoY)	26.12% (+20 bps YoY)	201.23 (+29.1% YoY)

Balance sheet & returns

ROCE (%)	ROE (%)	Net Debt to EBITDA (x)	Net Debt to Equity (x)
As on 30th Sept'26 24.30 (+216 bps YoY)	As on 30th Sept'26 26.34 (+134 bps YoY)	As on 30th Sept'26 1.07 (32.1% YoY Improvement)	As on 30th Sept'26 0.51 (37.9% YoY Improvement)

Consolidated Profit & Loss Account

Particulars (Rs. Cr.)	Q2FY27	Q2FY26	YoY	H1FY27	H1FY26	YoY	FY26
Revenue from operations	760.45	678.71		1,426.67	1,237.53		2,563.69
Other income	12.71	0.11		27.92	9.10		19.24
Total income	**773.16**	**678.82**	**13.9%**	**1,454.59**	**1,246.62**	**16.7%**	**2,582.92**
Raw Material	404.76	334.32		776.36	609.56		1,317.10
Power and fuel	50.93	45.49		96.87	84.38		173.69
Employee expense	29.81	29.02		59.72	56.41		114.71
Other expenses	75.16	87.85		141.67	173.08		311.97
EBITDA	**212.49**	**182.14**	**16.7%**	**379.96**	**323.19**	**17.6%**	**665.45**
EBITDA margin	**27.5%**	**26.8%**	**65 bps**	**26.1%**	**25.9%**	**20 bps**	**25.8%**
Depreciation	37.04	35.60		74.40	71.81		143.80
EBIT	**175.45**	**146.54**		**305.56**	**251.39**		**521.66**
Finance cost	16.90	21.47		33.65	45.14		81.95
Profit before tax	**158.55**	**125.07**		**271.92**	**206.25**		**439.70**
Tax	41.02	34.86		71.54	58.49		122.98
Profit after tax	**117.53**	**90.21**	**30.3%**	**200.37**	**147.76**	**35.6%**	**316.72**
PAT atributable to NCI	0.51	(3.70)		(0.86)	(8.08)		(10.82)
PAT atributable to Company	**117.03**	**93.91**	**24.6%**	**201.23**	**155.85**	**29.1%**	**327.54**
PAT margin	**15.1%**	**13.8%**	**130 bps**	**13.8%**	**12.5%**	**133 bps**	**12.7%**
EPS	29.96	24.04		51.52	39.90		83.85

Consolidated Balance Sheet

Assets (Rs Cr.)	Sept-26	Mar-26
Non Current Assets		
Property, Plant and Equipment	1,044.38	1,111.68
Capital work-in-progress	453.01	297.65
Intangible assets	54.21	7.44
Intangible assets Under Development	7.70	16.12
Right of use assets	20.62	49.38
Financial Assets		
Investments	1.10	0.91
Other financial assets	24.60	22.73
Income Tax Asset	20.77	7.57
Other non-current assets	103.13	60.44
Total Non Current Assets	**1,729.52**	**1,573.91**
Current Assets		
Inventories	845.77	826.07
Financial Assets		
Investments	87.01	53.59
Trade receivables	463.09	526.01
Cash and cash equivalents	73.95	44.09
Other bank balances	0.54	25.44
Other financial assets	1.49	1.47
Other current assets	169.20	119.24
Total Current Assets	**1,641.04**	**1,595.91**
Total Assets	**3,370.57**	**3,169.82**

Liabilities (Rs Cr.)	Sept-26	Mar-26
Equity		
Equity Share capital	39.06	39.06
Other Equity	1,536.08	1,373.37
Non Controlling Interest	27.31	28.17
Total Equity	**1,602.46**	**1,440.61**
Financial Liabilities		
Borrowings	571.30	577.90
Lease liabilities	6.28	2.70
Provisions	34.21	33.23
Deferred tax liabilities (Net)	21.99	22.69
Total Non Current Liabilities	**633.78**	**636.52**
Financial Liabilities		
Borrowings	405.49	431.99
Lease liabilities	8.64	8.68
Trade Payables	583.76	527.42
Other financial liabilities	72.85	103.02
Provisions	5.61	3.66
Other current liabilities	53.56	14.90
Current tax liabilities (Net)	4.42	3.03
Total Current Liabilities	**1,134.33**	**1,092.69**
Total Equity and Liabilities	**3,370.57**	**3,169.82**

Consolidated Cashflow

Particulars (Rs. Cr.)	H1 FY27	FY26
Net Profit Before Tax	**271.92**	**439.70**
Adjustments for: Non Cash Items / Other Investment or Financial Items	86.73	236.03
Operating profit before working capital changes	**358.65**	**675.74**
Changes in working capital	85.76	-9.31
Cash generated from/(used in) operations	**444.40**	**666.42**
Direct taxes paid (net of refund)	-84.14	-116.34
Net Cash from Operating Activities	**360.26**	**550.09**
Net Cash from Investing Activities	**-220.21**	**-358.08**
Net Cash from Financing Activities	**-110.19**	**-197.67**
Net Decrease in Cash and Cash equivalents	**29.86**	**-5.66**
Add: Cash & Cash equivalents at the beginning of the period	44.09	49.76
Cash & Cash equivalents at the end of the period	**73.95**	**44.10**

Q2 Performance across years









Annual Performance

Total Income (Rs. In Cr)



EBITDA (Rs. In Cr)



EBITDA Margin (%)



PAT (Rs. In Cr) / Margin (%)



Net Debt (Rs. In Cr) & Net Debt / Equity (x)



Net Debt / EBITDA (x)



Net Working Capital (No. of days)



ROCE & ROE (%)



* On a Consolidated Basis

COMPANY OVERVIEW

PRIVI SPECIALITY CHEMICALS LIMITED

India's Leading Aroma Chemicals Manufacturer

A 30+ year track record of building global leadership in pine- based and speciality aroma chemicals — supplying the world's top fragrance and FMCG companies.

75+
Products

48,000 MTPA
Production Capacity

2 R&D CENTRES
Dedicated Centres driving innovation

7
State of art Manufacturing Facilities

40+
Exports to Countries

36,000 MTPA
CST Processing Capacity

12,000 MTPA
GTO Processing Capacity

70%
Raw Materials Used are derived from Renewable Resources

Strategically Located
Near JNPT Port & Ankleshwar Dry Port

Our Journey

2023
Crossed turnover of Rs 1,500 Crores
Launched Galaxmusk, Camphor and Prionyl.

2025
Turnover crossed Rs. 2,000 Crores.
Comissioned and commenced commercial production at PRIGIV

2026
Turnover crossed Rs. 2,500 Crores.

Way Forward
Working on 5K:1K plan

2021
Promoter bought back Fairfax equity
Announced JV with Givaudan SA as PRIGIV

2020
Demerged from Fairchem Speciality
Name change to Privi Speciality Chemicals Ltd, independently listed

2019
Turnover crossed Rs 1000 Cr.

2017
Indirectly listed as subsidiary of Fairchem Speciality

2011
Private Equity Investment by Standard Chartered

2012
Backward integration by setting up CST & GTO capacity

2014
Longer term contracts – Givaudan SA, P&G, Henkel
Started commercial production at Unit- VI Gujarat

2016
Private Equity Investment by Fairfax

2007
Infusion of Private Equity Capital by Avigo

2005
Turnover crossed Rs 100 Cr.

1997
Commenced First Export to Germany

1993
Started manufacturing aroma chemicals.

Geographical Presence



2 Manufacturing Sites

7 Distribution Centres

3 Stocking Points

Serving **40+** Countries

Disclaimer: This map is a generalised illustration only for the ease of the reader to understand the locations, and it is not intended to be used for reference purposes. The representation of political boundaries and the names of geographical features/states do not necessarily reflect the actual position. Our Company or any of our Directors, officers or employees cannot be held responsible for any misuse or misinterpretation of any information or design thereof. Our Company does not warrant or represent any kind of connection with its accuracy or completeness.

Competitive Advantages

Backward Integration

- **Integrated inhouse developed CST processing** for manufacturing key raw material for pine-based products
- CST process know-how and sourcing is a **prominent entry barrier, offering Privi a significant advantage vs. peers**
- Margin stability - Procuring CST at a long term contracts

Robust Manufacturing

- Privi's state-of-the-art **manufacturing capacities are amongst the largest globally**
- Manufacturing infrastructure has the **best-in-class regulatory compliance & certifications**

R&D Capabilities

- **Substantial and long-term emphasis on R&D** with process scale up, project implementation being done in-house
- Track-record of **successfully commercializing multiple products from R&D phase to scale up**

PRIGIV — Strategic JV with Givaudan

PRIVI

51%

- India's leading manufacturer of aroma and fragrance chemicals
- Globally trusted partner and a preferred supplier of bulk aroma chemicals

+

Givaudan

49%

- Swiss multinational manufacturer of flavours, fragrances and active cosmetic ingredients
- World's largest company in the flavour and fragrance industries

- **Dedicated product portfolio:** Manufacturing **more than 40+ specialty products exclusively for Givaudan**
- **Expansion :** Privi and Givaudan together invested Rs. 50 crores as equity : **Project under implementation**
- **High-Value Specialty Expansion:**
  Evaluating additional CAPEX to manufacture high-value specialty molecules using in-house technology, with potential revenue of **~Rs. 100+ crore**

High R&D focus to develop new products and processes

02 **R&D Centers at Mahad and Nerul**

117 **R&D team strength** **including scientist, microbiologist & chemistry professionals**

DSIR recognition for both R&D centres extended till 2029



- Synthetic Organic Research lab and Pilot plants are approved by the Department of Scientific and Industrial Research (DSIR), Ministry of Science and Technology.
- Well equipped with new instruments & machinery like GCMS, GLCS, FTIR, UV Spectrophotometer, Refractometer, Polarimeter, Colorimeter, Bomb Calorimeter, Reaction, Distillation and Recovery Units
- Improving yield and process for future development on continues basis

Operational Excellence : Driving Efficiency, Quality & Sustainability

Safety & People

- Regular safety audits and emergency drills
- Skilling programs & Kaizen for continuous improvement
- Culture of urgency, transparency & care through the 5S Values

Sustainability

- About 70% raw materials from renewable sources
- Energy, water, and waste reduction programs
- Zero Liquid Discharge (ZLD) facilities in place
- Solvent recovery, by-product valorization

R&D & Quality

- 2 R&D centers (Mahad & Nerul)
- 114-member R&D team with scientists, microbiologists, chemists
- Concept-to-Commercialisation framework ensures faster time-to-market
- Focus on biotechnology, synthetic innovations & green chemistry

Process Efficiency

- Continuous process improvement leading to better Yields
- Strong cost discipline and operational controls driving profitability
- Energy efficiency improvement to save utility cost

Asset & Capacity

- Capacity debottlenecking across plants
- Preventive and Predictive maintenance systems in place
- Capacity Expansion plan

GROWTH STRATEGY

PRIVI SPECIALITY CHEMICALS LIMITED

Marching towards Vision – 5k | 1k Milestone*

New Projects and Products

- Existing products expansion
- Maltol and Ethyl Maltol
- Renewable Cyclopentanone
- 10+ other High end Specialty Products
- Furfural
- 40+ Products under PRIGIV

On track to achieve the vision of **Rs 5,000 Cr revenue** and **Rs 1,000 Cr + EBITDA** by FY29-30, representing more than 2x growth.

EBITDA margins are expected to sustain north of **20%**, driven by continued operational efficiency and an enhanced product mix

** The above figures are based on management estimates and are subject to change depending on external factors and requisite approvals.*

Proposed Scheme of Amalgamation

Privi Fine Sciences Private Limited (PFSPL) + **Privi Biotechnologies Private Limited (PBPL)** + **Privi Speciality Chemicals Limited (PSCL)**

Key Rationale

Diverse Product Portfolio
PFSPL includes Privial, Anethole, and Cyclamen Aldehyde used in fine and functional flavours and fragrances

Innovation-Driven
Research focused on converting corn and cob into high-value products like Furfural and its derivatives

Biotech-Focused R&D
PBPL, a 100% subsidiary, specializes in biotechnology-driven flavour and fragrance development

Strategic Merger
Planned integration with the parent company to strengthen core operations and enhance agility

Green Science Advantage
Expands offerings through sustainable chemistry solutions

Growth Enabler
Product and R&D capabilities expected to drive long-term business growth

Green Science Vision
Aligns with the company's belief in sustainable, nature-like aroma chemicals

Synergistic Growth
Merger expected to unlock faster growth through combined expertise in aroma chemicals

Key Growth Levers



Existing Product Expansion

Expanding the reach of current products to increase sales

New Product Innovation

Introducing new products, in synergy with existing raw material

Gross Margin Expansion

Improving profitability by increasing gross margins

Efficient Working Capital Management

Optimizing working capital to enhance liquidity and operational efficiency

Incentive

State tax incentive against CAPEX done

China +1 Strategy

Diversifying supply chains with a focus on China and additional markets

Key Business Highlights 5k:1k and beyond

Expansion Projects

Speciality molecule expansion projects progressing.

Biorefinery

Significant progress in scaling biomass conversion technologies.

Intellectual Property

Technology group creating IP rights for new technologies.

In-house talent

Privi harnessing in-house talent for increased responsibilities.

Capacity Augmentation

Flagship product capacity augmentation project nearing completion.

Information Technology

Strengthening its Information Technology and Systems to use Artificial Intelligence tools

Thank You

For further queries, Please contact:

Company :
Mr. Sanjeev Patil
Executive Vice President - Strategy
investors@privi.co.in
www.privi.co.in

Investor Relations Advisors :
Adfactors PR Pvt. Ltd.
Rushabh Shah: rushabh.shah@adfactorspr.com
M: +91 8082180182
Pratik Shah: pratik.shah@adfactorspr.com
M: +91 9870030585